AR Solutions in Action - Fiscal Year 2023

Rapid Detection & Response: State, territory, and local public health partners fight AR in health care, the community, and food.
Funding Amount: $1,981,659 (Includes funding to New York City)
CDC-funded HAI/AR Programs form a network of health departments that detect, prevent, respond to, and contain HAI/AR threats and promote appropriate use of antibiotics and antifungals. CDC’s AR Lab Network provides nationwide lab capacity to rapidly detect AR and inform local prevention and response activities to stop the spread of antimicrobial-resistant germs and protect people.

Food Safety projects protect communities by rapidly identifying antimicrobial-resistant foodborne bacteria to stop and solve outbreaks and improve prevention.
Funding Amount: $1,126,873 (Includes funding to New York City)
New York uses whole genome sequencing to track outbreaks and identify AR genes and shares surveillance data with PulseNet. Local CDC-supported epidemiologists respond to outbreaks to stop their spread. The Food Safety Center of Excellence supports other health departments to track and investigate foodborne diseases. New York conducts active, population-based surveillance for foodborne diseases through CDC’s Emerging Infections Program.

Fungal Disease projects improve our ability to track resistance to antifungals and stop it from spreading.
Funding Amount: $77,015
New York conducts surveillance to identify fungal diseases, monitor for new and emerging AR, and implement strategies to prevent the spread of AR in high-risk areas. New York conducts population-based surveillance for Candida bloodstream infections through CDC's Emerging Infections Program.

Drug-resistant Gonorrhea Detect & Respond Program works with state and local epidemiology and laboratory partners to test for and quickly respond to resistant gonorrhea to stop its spread in high-risk communities. Only one recommended treatment option remains for gonorrhea and resistance to other antibiotics continues to grow.
Funding Amount: $971,864 (Includes funding to New York City)
Strengthening the U.S. Response to Resistant Gonorrhea (SURRG) tests for and responds to antimicrobial-resistant gonorrhea cases in high-burden communities. The Gonococcal Isolate Surveillance Project (GISP) informs treatment guidelines by monitoring how well antibiotics work on samples collected from STD clinics. The STD Surveillance Network (SSuN) monitors adherence to gonorrhea treatment guidelines. This work is supported by CDC STI, AR, and HIV funds.

Global Migration, Border Interventions, and Migrant Health Programs support state partner efforts to prevent the spread of infectious diseases, including drug-resistant tuberculosis, into the United States.
Funding Amount: $50,000 (Includes funding to New York City)
Experts conduct surveillance and outbreak investigations for tuberculosis (TB) among populations seeking asylum in the United States and currently living in shelters and other similar facilities. These efforts help to determine rates of TB among this population.

The Emerging Infections Program (EIP) HAI component helps answer critical questions about emerging HAI threats, advanced infection tracking methods, and AR in the United States.
Funding Amount: $2,517,089
The New York EIP performs population-based surveillance for candidemia, Clostridioides difficile, invasive Staphylococcus aureus, nontuberculous mycobacteria, and resistant gram-negative bacteria. They also conduct HAI and antimicrobial use prevalence surveys and participate in a surveillance pilot for Escherichia coli infections to help support vaccine evaluation.
Learn more: www.cdc.gov/hai/eip

Emerging Infections Program (EIP) sites improve public health by conducting population-based surveillance and research activities that inform policy and public health practice.
Funding Amount: $50,000
EIP Active Bacterial Core surveillance (ABCs) is an active laboratory- and population-based surveillance system for invasive bacterial pathogens of public health importance. ABCs provides an infrastructure for further public health research, which may include special studies to identify disease risk factors, evaluate vaccine efficacy, and monitor the effectiveness of prevention policies.
Learn more: www.cdc.gov/abcs

New York City Health + Hospitals: Innovative Prevention & Tracking
Funding Amount: $425,239
CDC’s Project Firstline is a collaborative of diverse partners that provides engaging, innovative, and effective IPC training for U.S. healthcare workers and the public health workforce. It offers resources in a variety of formats to meet the diverse learning needs and preferences of the healthcare workforce. Partners host events, create tools, and publish resources that help healthcare workers better understand and correctly implement IPC.
Learn more: www.cdc.gov/infectioncontrol/projectfirstline

ICAP at Columbia University: Global Expertise & Capacity Enhancements
Funding Amount: $485,000
CDC’s global work to combat AR helps prevent the importation of AR threats into the United States. Experts implement activities to combat the spread of AR in Ukraine in collaboration with the Ukraine Ministry of Health, including improving diagnostic capacity to detect AR, enhancing IPC practices to prevent surgical site infections and AR transmission, and ensuring antibiotic access and appropriate use.

ICAP at Columbia University: Global Expertise & Capacity Enhancements
Funding Amount: $200,000
CDC’s global work to combat AR helps prevent the importation of AR threats into the United States. Experts support the Global Healthcare Detection and Response (DARE) AR Project in Kenya to improve detection, monitoring, and mitigation of AR. They also estimate the AR burden, enhance surveillance, improve antibiotic stewardship, and develop quality improvement capacity for antibiotic use and IPC.

Additional Notes

Acronyms